Drugs / Epaminurad
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT07374406 | Feb 2026 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT07036458 | Aug → Sep 2025 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06665425 | Mar → May 2025 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 1 | NCT06435442 | Jun 2024 → Dec 2025 | — | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05815901 | Mar 2023 → Mar 2024 | gout | JW Pharmaceutical | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Epaminurad | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06665425 ↗ |
| Known as | UR-1102 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4640580 ↗ |
| Modality | Small molecule | — CHEMBL4640580 ↗ |
| Route | Oral | “Oral Solution” NCT07036458 ↗ |